Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Grifols ( (ES:GRF) ) just unveiled an update.
Grifols has announced that its subsidiary, Grifols Biotest Holdings GmbH, will submit a public offer to purchase all ordinary and non-voting preferred shares of Biotest AG for delisting. This strategic move aims to enhance Grifols’ market position by integrating Biotest’s operations, with the offer subject to approval by the German Federal Financial Supervisory Authority.
More about Grifols
Grifols is a global healthcare company specializing in the production of plasma-derived medicines and transfusion medicine. The company focuses on enhancing the health and well-being of people around the world through innovative solutions in the biopharmaceutical industry.
YTD Price Performance: -5.35%
Average Trading Volume: 219,514
Technical Sentiment Signal: Strong Buy
Current Market Cap: €5.34B
Find detailed analytics on GRF stock on TipRanks’ Stock Analysis page.